Irbesartan Ratiopharm (Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. This results in relaxed blood vessels, reduced peripheral resistance, and decreased sodium‑water retention, which together lower blood pressure and provide renal protection.

The exact dose of Irbesartan Ratiopharm is determined by the prescribing clinician based on the individual’s blood‑pressure level, renal function, and response to therapy. Typical starting doses range from low to moderate, with adjustments made according to clinical monitoring.

Irbesartan is generally contraindicated during pregnancy because it can cause fetal toxicity, especially in the second and third trimesters. Limited data are available for breastfeeding; therefore, the drug should be used only if the potential benefit outweighs the possible risk to the infant.

To place an order, submit an enquiry on the Irbesartan Ratiopharm product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which offers similar blood‑pressure control to ACE inhibitors but with a lower incidence of cough and angioedema. Both classes block the renin‑angiotensin system, yet ARBs act downstream at the AT1 receptor, providing an alternative for patients intolerant to ACE inhibitors.

Irbesartan Ratiopharm should be stored at room temperature, below 25 °C, in its original blister or bottle. Keep the product away from moisture, direct sunlight and excessive heat. Do not store in the bathroom or near a kitchen sink to maintain tablet integrity.

Irbesartan Ratiopharm is taken orally, usually once daily. Tablets can be swallowed whole with water and may be taken with or without food. Patients should follow the prescribing physician’s instructions regarding timing and any necessary dose adjustments.

The most serious adverse events include hyperkalaemia, acute renal impairment, and angioedema. Patients should be educated to report sudden swelling of the face, lips or tongue, rapid changes in kidney function tests, or symptoms of high potassium such as muscle weakness or irregular heartbeat.

Irbesartan should not be used by individuals with known hypersensitivity to the drug or any ARB, pregnant women, or patients with severe hepatic impairment without careful monitoring. Caution is also advised in patients with bilateral renal artery stenosis or those taking other potassium‑increasing agents.